Page 1

ASX Announcement Quarterly Cash Flow Statement & Operational Highlights Highlights : • Strong cash position of $ 18.62 million Recce Pharmaceuticals recce.com.au ACN 124 849 065 • Phase I / II Topical Burn Wound Infections Clinical Trial - Multiple Patients Dosed • Phase I Intravenous Clinical Trial Registered in the Australian New Zealand Clinical Trials Registry ( ANZCTR ) • Innovation Connections Grant received under the Australian Government's Entrepreneurs ' Programme • • Bonus Canadian Scientific Research & Experimental Development Rebate received ( SR & ED ) R327 Efficacy Against Necrotizing Fasciitis ‘ Flesh - Eating ' Bacteria Anti - Viral Patent Granted in China and the United States SYDNEY Australia , 29 October 2021 : Recce Pharmaceuticals Ltd ( ASX : RCE , FSE : R9Q ) ( the Company ) , the Company developing New Classes of Synthetic Anti- infectives , today released its October 2021 quarter results and operational highlights . Financial Update The Company ended the quarter with a cash balance of $ 18.62 million . Net cash out- flows were ( $ 2.14 million ) with Research and Development ( $ 1.18 million ) the largest item of expenditure . Payments to related parties ( Executive & Director fees ) was ( $ 0.616 million ) . Bonus Canadian SR & ED Rebate Received In addition to the Australian 43.5 % R & D rebate , the Company captured a further 10 % ( A $ 183,444 ) in its first Canadian Government R & D rebate , as part of its Scientific Research & Experimental Development ( SR & ED ) Tax Incentive program ( booked 30 June 2021 , received and announced early July ) ASX : RCE , FSE : R9Q Head Office : Level 25 , 88 Phillip Street , Aurora Place , SYDNEY NSW 2000 T +61 ( 02 ) 9256 2571 R & D Centre - Perth : Suite 10 , 3 Brodie Hall Drive , Technology Park , BENTLEY WA 6102 T +61 ( 8 ) 9362 9860 Washington Office : 1717 Pennsylvania Avenue NW , Suite 1025 , WASHINGTON DC 20006 USA